Skip to main content
. 2009 Nov 16;101(3):609–615. doi: 10.1111/j.1349-7006.2009.01439.x

Figure 1.

Figure 1

 Upregulation of NKG2D ligand (NKG2DL) expression on leukemic cell lines by treatment with valproic acid (VPA). (a) Histograms of NKG2DL expression on three myeloid leukemia cell lines are shown. Green lines, untreated cells; purple lines, isotype control; red lines, VPA treated cells. (b) Changes in the mean fluorescence intensity (MFI) level of MICA/B and ULBP2 in various leukemic cell lines. Each column represents the difference in the MFI level calculated by subtracting the MFI level of untreated cells from that of VPA treated cells. The differences in the MFI levels are indicated as the mean + SD from three independent experiments. *P < 0.05. (c) Selective upregulation of NKG2DLs by VPA treatment on non‐apoptotic OUN‐1 cells. Apoptotic and non‐apoptotic cells defined by the expression of annexin V were separately assessed for the expression of NKG2DLs. Green lines, untreated cells; red lines, VPA treated cells. (d) Effect of various reagents on VPA‐induced MICA/B and ULBP2 expression by OUN‐1 cells. OUN‐1 cells were pretreated with the indicated reagent for 1 h and were incubated in the presence of VPA. Each column represents the difference in the MFI level calculated by subtracting the MFI level of untreated cells from that of VPA treated cells. BAPTA‐AM, calcium chelator; CsA, cyclosporine; FK506, tacrolimus; JNK‐1, an inhibitor of JNK; PD98059, an inhibitor of ERK1/2; SB202190, an inhibitor of p38MAPK.